Diuretics in Heart Failure - Pharmacology

SECTION 1

Historical Context & Motivation

Heart failure has been recognized as a clinical syndrome for centuries, with descriptions of edema and dyspnea appearing in texts dating back to Hippocrates. For most of medical history, physicians had few effective tools to combat the relentless fluid accumulation that defines congestive heart failure. Early treatments relied on botanical preparations such as foxglove (digitalis) for inotropy and mercurial compounds for their crude diuretic effects, but these approaches carried significant toxicity. The twentieth century brought a revolution in the pharmacological management of volume overload, beginning with the development of carbonic anhydrase inhibitors and culminating in the loop diuretics and aldosterone antagonists that remain cornerstones of heart failure therapy today.

1920s • Mercurial Diuretics

Organomercurial compounds such as mersalyl were among the first agents used to promote diuresis in edematous patients, though nephrotoxicity and heavy-metal poisoning limited their utility.

1950 • Acetazolamide Introduced

The carbonic anhydrase inhibitor acetazolamide became available, offering the first non-mercurial oral diuretic. Its weak natriuretic effect, however, limited its role as a primary agent in heart failure.

1957 • Chlorothiazide — The Thiazide Era Begins

Karl Beyer and colleagues at Merck developed chlorothiazide, the first thiazide diuretic, which rapidly replaced mercurials and transformed the treatment of hypertension and mild heart failure.

1964 • Furosemide — Loop Diuretics Emerge

Furosemide was approved for clinical use, targeting the thick ascending limb of the loop of Henle and providing far greater natriuretic potency than thiazides. It quickly became the mainstay for acute decompensated heart failure.

1999 • RALES Trial — Spironolactone Reduces Mortality

The Randomized Aldactone Evaluation Study demonstrated a 30% reduction in mortality with spironolactone in severe heart failure, cementing the role of mineralocorticoid receptor antagonists as disease-modifying agents.

The central question that drove these pharmacological advances remains highly relevant: how can we effectively reduce pathological volume overload — the hallmark of congestive heart failure — while preserving renal function, electrolyte homeostasis, and neurohormonal balance? Modern diuretic therapy answers this question through agents that target specific nephron segments, each with distinct efficacy profiles and adverse-effect considerations that clinicians must master.

SECTION 2

Core Principles of Diuretic Therapy in Heart Failure

To appreciate why diuretics are indispensable in heart failure management, one must first understand the pathophysiology they counteract. In heart failure, reduced cardiac output activates the renin-angiotensin-aldosterone system (RAAS) and the sympathetic nervous system, both of which drive avid sodium and water reabsorption by the kidneys. While these compensatory mechanisms initially maintain perfusion pressure, chronic activation leads to progressive volume expansion, elevated venous pressures, pulmonary congestion, and peripheral edema — the clinical manifestations of congestive heart failure. Diuretics interrupt this cycle by promoting renal excretion of sodium and obligated water, thereby reducing intravascular volume and cardiac preload.

Nephron Segment Specificity

Each class of diuretic acts at a distinct segment of the nephron — proximal tubule, thick ascending limb, distal convoluted tubule, or collecting duct. The site of action determines the maximum fraction of filtered sodium that can be excreted (the ceiling effect).

Dose-Response Relationship

Diuretics exhibit a sigmoidal dose-response curve. In heart failure, this curve is shifted rightward and downward due to reduced renal blood flow, tubular hypertrophy, and impaired drug delivery — a phenomenon termed diuretic resistance.

Electrolyte Consequences

By altering tubular sodium handling, diuretics inevitably affect potassium, magnesium, calcium, and acid-base balance. Understanding these electrolyte disturbances is essential for safe prescribing, particularly when multiple agents are combined.

Neurohormonal Activation

Aggressive diuresis can further activate the RAAS and sympathetic nervous system, paradoxically worsening the neurohormonal milieu of heart failure. This underscores the importance of combining diuretics with RAAS inhibitors, beta-blockers, and mineralocorticoid receptor antagonists.

✦

KEY TAKEAWAY

Think of the failing heart as a sump pump that can no longer keep up with water entering a basement. Diuretics do not fix the broken pump — they reduce the rate at which water flows in by opening drain valves at specific points along the plumbing (nephron segments). Opening a larger valve (loop diuretics at the thick ascending limb) drains water much faster than opening a small valve (thiazides at the distal tubule), but draining too aggressively can lower the water level below what the pump needs to function. This is why titrating diuretics in heart failure requires balancing decongestion against the risk of hypovolemia and worsening renal function.

SECTION 3

Nephron Sites of Diuretic Action

This diagram illustrates the four major nephron segments targeted by diuretics used in heart failure. Carbonic anhydrase inhibitors act at the proximal tubule where the bulk of sodium is reabsorbed. Loop diuretics target the thick ascending limb and produce the most potent natriuresis. Thiazide diuretics act at the distal convoluted tubule, while potassium-sparing agents and MRAs modulate sodium reabsorption at the collecting duct.

The diagram above provides a schematic overview of the nephron with each diuretic class positioned at its primary site of action. The percentages noted alongside each segment represent the approximate fraction of filtered sodium reabsorbed at that location under normal physiological conditions. The thick ascending limb is responsible for roughly 25% of sodium reabsorption, which explains why loop diuretics produce the most vigorous diuresis and are considered the agents of choice in acute decompensated heart failure. By contrast, the collecting duct handles only 2−3% of filtered sodium, which is why mineralocorticoid receptor antagonists are relatively weak natriuretic agents yet remain critically important for their neurohormonal and mortality-reducing benefits.

SECTION 4

Mechanisms of Action by Diuretic Class

Loop Diuretics — Inhibition of NKCC2

Loop diuretics such as furosemide, bumetanide, and torsemide reach the tubular lumen primarily via organic anion transporters in the proximal tubule. Once in the lumen, they bind to and inhibit the Na⁺/K⁺/2Cl⁻ cotransporter (NKCC2) on the apical membrane of epithelial cells in the thick ascending limb. By blocking NKCC2, these agents prevent the reabsorption of approximately 25% of filtered sodium. Because the thick ascending limb is also responsible for generating the medullary concentration gradient through countercurrent multiplication, loop diuretics impair the kidney's ability to concentrate urine, leading to the excretion of large volumes of dilute urine.

NKCC2 TRANSPORT

Na⁺ + K⁺ + 2Cl⁻ (lumen) → Na⁺ + K⁺ + 2Cl⁻ (cell)

Loop diuretics competitively inhibit the Cl⁻ binding site on NKCC2, preventing simultaneous cotransport of all three ions. Downstream, reduced intracellular K⁺ decreases the lumen-positive potential that normally drives paracellular reabsorption of Ca²⁺ and Mg²⁺, explaining the calciuria and magnesiuria seen with loop diuretic use.

Thiazide Diuretics — Inhibition of NCC

Thiazide and thiazide-like diuretics — including hydrochlorothiazide (HCTZ), chlorthalidone, and metolazone — inhibit the Na⁺/Cl⁻ cotransporter (NCC) in the distal convoluted tubule. Although this segment reabsorbs only about 5% of filtered sodium, thiazides play a crucial adjunctive role in heart failure when combined with loop diuretics — a strategy known as sequential nephron blockade. Metolazone is particularly important in heart failure because it retains efficacy even at low glomerular filtration rates, unlike HCTZ which loses effectiveness when GFR drops below approximately 30 mL/min.

Mineralocorticoid Receptor Antagonists (MRAs)

Spironolactone and eplerenone block the mineralocorticoid receptor (MR) in principal cells of the collecting duct. Under normal physiology, aldosterone binds to this nuclear receptor, promoting transcription of ENaC (epithelial sodium channels) and the basolateral Na⁺/K⁺-ATPase, resulting in sodium reabsorption and potassium secretion. By antagonizing aldosterone, MRAs reduce sodium retention and, critically, spare potassium — counterbalancing the hypokalemia induced by loop and thiazide diuretics. Beyond their modest diuretic effect, MRAs attenuate myocardial fibrosis, vascular inflammation, and cardiac remodeling driven by elevated aldosterone levels in heart failure, which accounts for their mortality benefit demonstrated in landmark trials such as RALES and EMPHASIS-HF.

Carbonic Anhydrase Inhibitors

Acetazolamide inhibits carbonic anhydrase in the proximal tubule, reducing bicarbonate reabsorption and creating a mild metabolic acidosis. Although seldom used as a standalone diuretic in heart failure, it has re-emerged as an adjunctive agent in the setting of diuretic resistance with concomitant contraction alkalosis. The 2022 ADVOR trial demonstrated that adding intravenous acetazolamide to loop diuretics in acute decompensated heart failure significantly improved decongestion without worsening renal function.

SECTION 5

Comparative Classification of Diuretics

This bar chart compares the natriuretic potency (percentage of filtered sodium excreted) across four diuretic classes. Loop diuretics dominate with approximately 25% natriuresis, while MRAs exert modest natriuretic effects but provide mortality benefit through neurohormonal modulation.

Diuretic Class	Prototype	Nephron Target	Onset / Duration (oral)	Key Adverse Effects
Loop diuretics	Furosemide, Bumetanide, Torsemide	NKCC2 — Thick ascending limb	30−60 min / 4−6 h (furosemide)	Hypokalemia, hypomagnesemia, ototoxicity, hyperuricemia, contraction alkalosis
Thiazides	HCTZ, Chlorthalidone, Metolazone	NCC — Distal convoluted tubule	1−2 h / 6−12 h (HCTZ)	Hypokalemia, hyponatremia, hypercalcemia, hyperglycemia, hyperuricemia
MRAs	Spironolactone, Eplerenone	MR — Collecting duct	24−72 h / up to 72 h	Hyperkalemia, gynecomastia (spironolactone), renal insufficiency
CA Inhibitors	Acetazolamide	Carbonic anhydrase — Proximal tubule	1−2 h / 6−12 h	Metabolic acidosis, hypokalemia, paresthesias, renal stones
ENaC Blockers	Amiloride, Triamterene	ENaC — Collecting duct	2−4 h / 12−24 h	Hyperkalemia, metabolic acidosis

Comparison of diuretic classes used in heart failure management

SECTION 6

Clinical Case — Managing Diuretic Resistance

A 68-year-old patient with NYHA Class III heart failure with reduced ejection fraction (HFrEF, LVEF 25%) presents with worsening dyspnea, 5 kg weight gain over one week, bilateral lower extremity edema, and elevated jugular venous pressure. The patient is currently receiving oral furosemide 80 mg twice daily, lisinopril 20 mg daily, carvedilol 25 mg twice daily, and spironolactone 25 mg daily. Despite adherent medication use and a 2 g sodium-restricted diet, the patient's urine output has decreased and congestion is progressing. How should the diuretic regimen be escalated?

Escalation Strategy for Diuretic Resistance

1
Step 1 — Assess for True Diuretic Resistance

Before escalating therapy, verify medication adherence and dietary sodium compliance. Check a spot urine sodium: a level below 50 mEq/L two hours after a loop diuretic dose suggests inadequate drug delivery to the tubule or insufficient sodium intake to create a concentration gradient. In this patient, adherence is confirmed and spot urine Na⁺ is 28 mEq/L, consistent with true diuretic resistance.

Spot urine Na⁺ = 28 mEq/L → inadequate natriuretic response confirmed
2
Step 2 — Convert to IV Loop Diuretic

In acute decompensation, gut edema can impair oral absorption of furosemide (bioavailability 10−100%, average ~50%). Converting to intravenous furosemide eliminates this variability. The IV equivalent of oral furosemide is approximately half the oral dose because of the improved bioavailability. Current oral dose: 80 mg BID = 160 mg/day oral. IV equivalent: 80 mg BID IV, or a continuous infusion of 10−20 mg/hr after a 40 mg bolus.

Convert to IV furosemide 80 mg BID (or continuous infusion 10−20 mg/hr)
3
Step 3 — Add Sequential Nephron Blockade

If IV loop diuretic alone remains insufficient after 24−48 hours, add a thiazide diuretic to block compensatory sodium reabsorption at the distal tubule (a phenomenon called braking phenomenon or distal tubular hypertrophy). Metolazone 2.5−5 mg orally, given 30 minutes before the loop diuretic, is the classic choice because it retains activity at low GFR. Alternatively, IV chlorothiazide 250−500 mg can be administered. This combination can produce dramatic diuresis, so electrolytes (K⁺, Mg²⁺, Na⁺) and renal function must be monitored every 6−12 hours.

Add metolazone 2.5−5 mg PO 30 minutes before IV furosemide
4
Step 4 — Consider Acetazolamide as Adjunct

Based on the ADVOR trial evidence, adding IV acetazolamide 500 mg once daily to the loop diuretic can enhance decongestion, particularly if the patient has developed contraction alkalosis (serum bicarbonate > 32 mEq/L) from chronic loop diuretic use. In this case, the patient's serum HCO₃⁻ is 34 mEq/L, making acetazolamide an appropriate addition.

Add acetazolamide 500 mg IV daily (serum HCO₃⁻ = 34 mEq/L)
5
Step 5 — Monitor and Adjust

Target a net negative fluid balance of 1−2 liters per day. Monitor daily weights, intake/output, serum creatinine, BUN, and electrolytes. Maintain serum K⁺ above 4.0 mEq/L (the patient is already on spironolactone, which helps offset potassium losses). If creatinine rises more than 0.3 mg/dL or the patient develops symptomatic hypotension, reduce or hold diuretic doses. Once euvolemia is achieved (resolution of edema, JVP normalization, weight stabilization), transition back to optimized oral diuretics.

Target: net negative 1−2 L/day; maintain K⁺ > 4.0 mEq/L; de-escalate upon euvolemia

SECTION 7

Risks, Benefits, and Limitations of Diuretic Therapy

Domain	Benefits	Risks / Limitations
Symptom Relief	Rapid reduction of dyspnea, orthopnea, and edema; improved exercise tolerance and quality of life	Symptom relief without proven mortality benefit for loop and thiazide diuretics (unlike MRAs)
Hemodynamics	Reduced preload lowers pulmonary capillary wedge pressure and relieves pulmonary congestion	Excessive diuresis may cause hypovolemia, hypotension, and cardiorenal syndrome; reduced cardiac output in preload-dependent patients
Electrolytes	MRAs counterbalance potassium wasting from other diuretics; combination strategies allow lower doses of individual agents	Hypokalemia and hypomagnesemia increase arrhythmia risk; hyperkalemia with MRAs, especially in CKD
Neurohormonal	MRAs reduce aldosterone-mediated cardiac fibrosis and remodeling; proven mortality reduction	Loop and thiazide diuretics activate RAAS and sympathetic nervous system reflexively, potentially accelerating disease progression if used without RAAS inhibitors
Renal Function	Decongestion may improve renal perfusion in patients with venous congestion-driven kidney injury	Diuretic resistance develops with chronic use; worsening renal function (WRF) occurs in up to 25% of hospitalized heart failure patients on aggressive diuresis

Benefits versus risks of diuretic therapy in heart failure

✦

KEY TAKEAWAY

Diuretics in heart failure are analogous to pressure-relief valves in an overloaded hydraulic system. They are essential for preventing the system from rupturing (pulmonary edema, anasarca), but they do not repair the underlying pump failure. Over-reliance on diuretics without addressing the root cause — through neurohormonal blockade with ACE inhibitors, ARBs, beta-blockers, MRAs, and SGLT2 inhibitors — is like continuously venting fluid from a leaking system without fixing the leak. Modern guideline-directed medical therapy (GDMT) treats diuretics as a symptomatic necessity that must always be paired with disease-modifying agents.

SECTION 8

Emerging Therapies and Advanced Considerations

The landscape of diuretic therapy in heart failure is evolving, driven by ongoing clinical trials and the integration of newer drug classes that indirectly modulate sodium and water handling. The most significant development in recent years has been the emergence of SGLT2 inhibitors (empagliflozin, dapagliflozin) as a pillar of heart failure therapy. Originally developed as antidiabetic agents, SGLT2 inhibitors block sodium-glucose cotransporter 2 in the proximal tubule, producing osmotic diuresis and mild natriuresis while also conferring direct cardioprotective and renoprotective effects. Unlike traditional diuretics, SGLT2 inhibitors do not significantly activate the RAAS, and landmark trials (DAPA-HF, EMPEROR-Reduced, DELIVER) have demonstrated mortality and hospitalization benefits across the spectrum of heart failure phenotypes.

Feature	Traditional Diuretics	SGLT2 Inhibitors
Mechanism	Block specific ion transporters along the nephron	Block SGLT2 in proximal tubule → glucosuria + osmotic diuresis
RAAS activation	Loop/thiazide diuretics activate RAAS reflexively	Minimal RAAS activation; may enhance tubuloglomerular feedback
Mortality benefit	Only MRAs have proven mortality benefit among traditional diuretics	Proven mortality and hospitalization benefit in HFrEF and HFpEF
Electrolyte effects	Significant K⁺, Mg²⁺, and Na⁺ disturbances	Minimal electrolyte disturbances; may mildly increase hematocrit (hemoconcentration)
Renal protection	May worsen renal function with aggressive dosing	Renoprotective; slows GFR decline in CKD

Traditional diuretics vs. SGLT2 inhibitors in heart failure

ℹ

Looking Ahead

Additional emerging approaches include vasopressin V2 receptor antagonists (tolvaptan) for hypervolemic hyponatremia, ultrafiltration for refractory congestion, and novel natriuretic peptide-based therapies. The concept of congestion-guided diuretic therapy — using biomarkers such as NT-proBNP and point-of-care ultrasound to titrate diuretic doses — represents a frontier in precision medicine approaches to heart failure management.

SECTION 9

Practice Problems

Question 1: CONCEPTUAL

Explain why loop diuretics have a greater natriuretic ceiling than thiazide diuretics. In your answer, reference the specific nephron segments and transporters involved.

Show answer

Loop diuretics inhibit NKCC2 at the thick ascending limb of the loop of Henle, where approximately 25% of filtered sodium is normally reabsorbed. Thiazide diuretics inhibit NCC at the distal convoluted tubule, which is responsible for only about 5% of sodium reabsorption. Because the thick ascending limb handles a far greater fraction of filtered sodium than the distal tubule, blocking transport at this site yields a proportionally greater natriuretic response. Additionally, loop diuretics disrupt the medullary concentration gradient, impairing the kidney's ability to concentrate urine and further augmenting water excretion.

Question 2: BASIC CALCULATION

A patient is receiving oral furosemide 120 mg daily at home. Due to acute decompensation, the physician decides to convert to intravenous furosemide. Given that oral furosemide has approximately 50% bioavailability while IV furosemide is 100% bioavailable, what total daily IV dose would provide an equivalent drug exposure? If the physician wants to give it as two equally divided doses, what is each dose?

Show answer

With 50% oral bioavailability, the 120 mg oral dose delivers approximately 60 mg of active drug systemically. Since IV administration achieves 100% bioavailability, the equivalent IV daily dose is 60 mg. Divided into two equal doses, each dose would be 30 mg IV. However, in clinical practice for acute decompensated heart failure, guidelines often recommend initiating IV therapy at a dose equal to or greater than the oral dose (i.e., ≥ 120 mg IV daily) to overcome diuretic resistance. The pharmacokinetic equivalence calculation provides a starting point, but clinical response — monitored through urine output and fluid balance — ultimately guides dosing.

Question 3: INTERMEDIATE

A heart failure patient on furosemide 80 mg IV BID develops a serum potassium of 2.9 mEq/L and serum bicarbonate of 36 mEq/L. Identify the electrolyte and acid-base disturbance, explain the mechanism by which loop diuretics cause each, and propose a management strategy.

Show answer

The patient has hypokalemia (K⁺ = 2.9 mEq/L, normal 3.5−5.0 mEq/L) and metabolic alkalosis (HCO₃⁻ = 36 mEq/L, normal 22−28 mEq/L), a classic combination termed contraction alkalosis. Loop diuretics cause hypokalemia by two mechanisms: first, increased sodium delivery to the collecting duct enhances Na⁺/K⁺ exchange via ENaC and ROMK, promoting potassium secretion; second, volume contraction stimulates aldosterone release, which further drives potassium excretion. The metabolic alkalosis results from loss of H⁺ and Cl⁻ in the urine, volume contraction concentrating existing bicarbonate, and enhanced proximal tubule bicarbonate reabsorption driven by hypovolemia. Management includes aggressive potassium and magnesium repletion (magnesium is required for K⁺ repletion to be effective), addition of acetazolamide to counteract the alkalosis, and consideration of increasing the spironolactone dose if tolerated.

Question 4: APPLIED

A 72-year-old patient with HFrEF (LVEF 20%) and chronic kidney disease (eGFR 22 mL/min/1.73 m²) is admitted with severe volume overload. The patient is on oral furosemide 160 mg BID but urine output has fallen to 400 mL/day. Outline a comprehensive diuretic escalation strategy, justifying each choice in the context of the patient's renal impairment.

Show answer

In severe CKD (eGFR 22 mL/min), several factors contribute to diuretic resistance: reduced renal blood flow limits drug delivery to the tubule, accumulated organic anions compete with furosemide for secretion by proximal tubule OAT transporters, and distal tubular hypertrophy increases compensatory sodium reabsorption. The strategy should proceed as follows. First, convert to IV furosemide at a dose at least equivalent to the oral dose — given the high oral dose and poor response, start with 160−200 mg IV boluses or a continuous infusion at 20−40 mg/hr after a 80 mg loading dose (continuous infusion may reduce ototoxicity risk at high doses). Second, add metolazone 5−10 mg PO, which is preferred over HCTZ because metolazone retains efficacy at low GFR; administer 30 minutes before the loop diuretic. Third, consider adding IV acetazolamide 500 mg daily, particularly if contraction alkalosis is present. Fourth, ensure adequate perfusion pressure — if the patient is hypotensive, inotropic support (e.g., dobutamine or milrinone) may be needed to improve renal perfusion and diuretic delivery. If pharmacological strategies fail after 48−72 hours, mechanical ultrafiltration should be discussed. Throughout, monitor potassium closely (CKD patients are at higher risk for hyperkalemia, especially with MRAs), and consider holding spironolactone if K⁺ exceeds 5.5 mEq/L.

Question 5: CRITICAL THINKING

Critically analyze the paradox that loop diuretics — the most widely used agents in heart failure — have never been shown to reduce mortality in randomized controlled trials, whereas mineralocorticoid receptor antagonists, which are weak diuretics, reduce mortality by approximately 30%. What does this paradox reveal about the pathophysiology of heart failure and the goals of pharmacotherapy?

Show answer

This paradox illuminates a fundamental distinction in heart failure pharmacotherapy between symptomatic (hemodynamic) relief and disease-modifying (neurohormonal) therapy. Loop diuretics address the downstream consequence of heart failure — sodium and water retention leading to congestion — without modifying the maladaptive neurohormonal activation that drives disease progression. In fact, by reducing intravascular volume, loop diuretics may paradoxically stimulate the RAAS and sympathetic nervous system, perpetuating the vicious cycle of neurohormonal activation, cardiac remodeling, and progressive ventricular dysfunction. MRAs, despite their modest natriuretic effect, directly antagonize aldosterone — a hormone that drives myocardial fibrosis, endothelial dysfunction, vascular inflammation, baroreceptor dysfunction, and potassium/magnesium wasting. The RALES and EMPHASIS-HF trials demonstrated that blocking these pathological effects of aldosterone translates into a survival advantage that far exceeds what would be predicted from the small diuretic effect alone. This paradox underscores the modern understanding that heart failure is fundamentally a neurohormonal disease, and that the most effective pharmacological interventions are those that interrupt maladaptive signaling pathways rather than simply relieving fluid accumulation. It also explains why current guidelines position loop diuretics as necessary for symptom management but require concurrent neurohormonal blockade with RAAS inhibitors, beta-blockers, MRAs, and SGLT2 inhibitors as the true disease-modifying backbone of therapy.

SUMMARY

Diuretics in Heart Failure — Summary

Summary

Diuretics remain indispensable for managing volume overload and congestion in heart failure, with each class targeting a specific nephron segment. Loop diuretics (furosemide, bumetanide, torsemide) inhibit NKCC2 at the thick ascending limb, producing the most potent natriuresis (~25% of filtered Na⁺) and serving as first-line agents in acute decompensation. Thiazide diuretics block NCC at the distal tubule and are used adjunctively in diuretic resistance via sequential nephron blockade. Mineralocorticoid receptor antagonists (spironolactone, eplerenone) provide modest natriuresis but critically reduce mortality through neurohormonal modulation and attenuation of cardiac fibrosis.

Key clinical considerations include monitoring for electrolyte disturbances (hypokalemia, hypomagnesemia, contraction alkalosis with loop/thiazide agents; hyperkalemia with MRAs), recognizing and managing diuretic resistance through dose escalation, IV conversion, and combination therapy, and always pairing diuretics with guideline-directed medical therapy (GDMT) — including RAAS inhibitors, beta-blockers, MRAs, and SGLT2 inhibitors — to achieve both symptomatic relief and disease modification. Understanding the pharmacological rationale behind each diuretic class empowers clinicians to tailor therapy to the individual patient's hemodynamic status, renal function, and electrolyte profile.